Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;57(8):1303-1310.
doi: 10.1111/head.13144. Epub 2017 Jul 30.

The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes

Stacy V Smith  1 , Deborah I Friedman  1   2
Affiliations
Review

The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes

Stacy V Smith et al. Headache. 2017 Sep.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Headache. 2018 Nov;58(10):1697. doi: 10.1111/head.13454. Epub 2018 Nov 7. Headache. 2018. PMID: 30481386 No abstract available.

Abstract

Objective: The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) was the first large, randomized study on the use of acetazolamide and weight loss for treatment of idiopathic intracranial hypertension-associated vision loss. The multicenter trial also examined a number of secondary outcomes. This review summarizes all available results of the study published in the literature since 2014.

Background: Prior to the IIHTT, clinicians managed idiopathic intracranial hypertension based on data from small, unmasked trials, expert opinion, and clinical experience. Due to the lack of empiric evidence, there were no official treatment protocols to guide treatment of the disorder.

Methods: We performed a PubMed literature search for all articles with data from the IIHTT Study Group. After review of each article and any relevant supporting literature, the results were compiled into a summary of the literature.

Results: The PubMed search identified 14 articles with primary and/or secondary outcome data from the IIHTT. We summarized the findings for the primary outcome of visual field outcomes in the acetazolamide treatment group compared to the placebo group, as well as secondary outcomes for the safety and tolerability of acetazolamide, cerebrospinal fluid opening pressure, quality of life, fundus photography, and optical coherence tomography. While both groups demonstrated improvement on most outcomes, acetazolamide had a greater effect even when controlling for its effect on weight loss.

Conclusions: As the first large, randomized, prospective trial, the IIHTT extensively expanded the available data on idiopathic intracranial hypertension treatment. Most importantly, it provided support for the safe use of acetazolamide up to 4 g daily with weight loss for effective treatment of mild vision loss in IIH, with associated improvements in papilledema, increased intracranial pressure, and quality of life.

Keywords: acetazolamide; automated perimetry; idiopathic intracranial hypertension; optical coherence tomography; pseudotumor cerebri; vision loss.

PubMed Disclaimer

MeSH terms

Substances